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Abstract
Chronic respiratory disorders are important contributors to the global burden of disease. Genome-wide association studies
(GWASs) of lung function measures have identiﬁed several trait-associated loci, but explain only a modest portion of the
phenotypic variability. We postulated that integrating pathway-based methods with GWASs of pulmonary function and airﬂow
obstruction would identify a broader repertoire of genes and processes inﬂuencing these traits. We performed two independent
GWASs of lung function and applied gene set enrichment analysis to one of the studies and validated the results using the second
GWAS. We identiﬁed 131 signiﬁcantly enriched gene sets associated with lung function and clustered them into larger biological
modules involved in diverse processes including development, immunity, cell signaling, proliferation and arachidonic acid. We
found that enrichment of gene sets was not driven by GWAS-signiﬁcant variants or loci, but instead by those with less stringent
association P-values. Next, we applied pathway enrichment analysis to a meta-analyzed GWAS of airﬂow obstruction. We
identiﬁed several biologic modules that functionally overlapped with those associated with pulmonary function. However,
differences were also noted, including enrichment of extracellular matrix (ECM) processes speciﬁcally in the airﬂow obstruction
study. Network analysis of the ECM module implicated a candidate gene, matrix metalloproteinase 10 (MMP10), as a putative
disease target. We used a knockout mouse model to functionally validateMMP10’s role in inﬂuencing lung’s susceptibility to
cigarette smoke-induced emphysema. By integrating pathway analysis with population-based genomics, we unraveled biologic
processes underlying pulmonary function traits and identiﬁed a candidate gene for obstructive lung disease.
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Introduction
Spirometric measurement of pulmonary function is the most
commonly used method to assess the lung’s physiologic and
pathophysiologic state. Forced expiratory volume in the ﬁrst se-
cond (FEV1) and its ratio to forced vital capacity (FEV1/FVC) are her-
itable traits that reproducibly measure airﬂow obstruction and
predictmorbidityandmortality in thegeneral population (1,2). Im-
pairment of FEV1 and FEV1/FVC are key criteria for the diagnosis
of chronic obstructive lung disease (COPD)—a highly morbid con-
dition predicted to become the third leading cause of death
worldwide by 2030 (3). We have previously reported on two inde-
pendent, large genome-wide association studies (GWASs) of pul-
monary function, each comprising over 20 000 individuals of
European ancestry (4,5). These studies, in combination with our
recent results based on larger joint meta-analyses, have identiﬁed
multiple loci associatedwith pulmonary function (6,7) and airﬂow
obstruction (8). However, genetic variants at these regions explain
<5% of the observed variance in spirometric traits (6), strongly im-
plying that a substantial portion of the available genetic contribu-
tion to variability in lung function is not identiﬁed using standard
GWAS statistical thresholds.
One promising approach to uncover the genetic underpinnings
of complex phenotypes is to reach beyond genome-wide signiﬁ-
cant hits to extract information from the entire association dataset
and discover sets of pathways linked to a given clinical trait (9).
Genes do not exert their effects in isolation, but rather cooperate
within pathways and larger biologic modules to inﬂuence disease
susceptibility and progression (10,11). Pathway-based analysis is
built on the premise that complex, polygenic phenotypes arise
fromdistinctmolecularpathways, and that small genetic perturba-
tions (i.e. single-nucleotide polymorphisms or SNPs) at multiple
siteswithin these gene sets can lead to the observed traits anddis-
eases. This paradigm allows implementation of statistical tests
that substantially relax cutoffs for statistical signiﬁcance, such
that a pathway can be enriched in a phenotype even though the
individual SNPs do not achieve genome-wide signiﬁcance. Several
publications have applied pathway-based approaches to previously
generated GWAS data and demonstrated the power of this method
in identifying previously undetected mechanisms (12–14).
This studywas designed to test the hypothesis that the genetic
basis of pulmonary function and airﬂow obstruction is orche-
strated by identiﬁable sets of functionally coherent pathways.
Initially, we implemented a robust methodology based on gene
set enrichment analysis (GSEA) (15,16) to identify and validate
pathways linked to lung function by step-wise leveraging of two
independent pulmonary function GWAS datasets. We then
applied this procedure to the largest available GWAS of airﬂow
obstruction (8). Our integrative approach systematically mapped
pathways associated with lung function and airﬂow obstruction
to functionally distinct modules, and lead to the identiﬁcation of
a putative COPD candidate.
Results
Staged analysis of lung function GWAS identiﬁes
and conﬁrms a large repertoire of enriched gene sets
We performed two separate GWASs of pulmonary function (FEV1
and FEV1/FVC) using two large consortia—CHARGE and SpiroMe-
ta. Cohort details are provided in Supplementary Material,
Table S1. Quantile–quantile (QQ) plots of observed versus ex-
pected association P-values showed signiﬁcant deviations from
the null hypothesis for each lung function measure, indicating
that many SNPs were strongly linked to these traits (Supplemen-
tary Material, Fig. S1). As outlined in Figure 1, after completing
standard GWAS for each consortium, we initially applied GSEA
to the CHARGE pulmonary function GWAS and identiﬁed 444
overrepresented gene sets associated with FEV1 or FEV1/FVC
(FDR < 0.05). We validated these ﬁndings by implementing the
same procedure for the SpiroMeta GWAS. Of the 444 pathways
identiﬁed in CHARGE, 131 were also enriched in SpiroMeta (FDR
< 0.05). Further analysis was restricted to these 131 gene sets that
were signiﬁcantly enriched in both independent studies. A com-
plete list of consortium-speciﬁc gene sets is available in Supple-
mentary Material, Table S2. To assess robustness of our ﬁndings,
we performed an identical two-step pathway enrichment meth-
od using a different program known as GSA-SNP (17) and found
broad overlap between processes enriched in both approaches
(see Supplementary Material, Table S4).
Enrichment of pathways is driven by SNPs moderately
associated with pulmonary function
To assess the relative contribution of SNPs to gene set enrichment,
we performed sensitivity analyses to verify that our ﬁndings
were not due to a disproportionate contribution by a few, highly
signiﬁcant SNPs. First,we repeatedGSEAafterexcludingall GWAS-
signiﬁcant SNPs (i.e. those with association P < 5 × 10–8). No differ-
ences were found in the list of enriched pathways. Next, we
expanded our analysis by additionally excluding all SNPs (regard-
less of P-value) within 100 Kb in either direction from all GWAS-
signiﬁcant loci. Again, we did not observe any appreciable change
in the enrichment proﬁle of gene sets. While genes in enriched
pathways included several GWAS-signiﬁcant loci, most genes
weremapped to SNPswithmoderate association P-values ranging
from 10–2 to 10–6 (SupplementaryMaterial, Fig. S2). These observa-
tions imply that a rich repository of genomic information rests
within a stratum of association P-values that is ignored in stand-
ard GWAS procedures.
Figure 1.Outline of the staged approach for pathwayanalysis of lung function.We
performed standard GWAS of pulmonary function measures in two large,
independent consortia: CHARGE and SpiroMeta. Gene set enrichment analysis
was initially applied to the CHARGE consortium’s pulmonary function GWAS
(Step 1), and subsequently performed on SpiroMeta’s GWAS (Step 2). Only
pathways that were signiﬁcantly enriched in Step 1 and replicated in Step 2
were used for further analysis.
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Pathway-associated SNPs are enriched in DNase I
hypersensitive sites
We investigated whether sentinel SNPs associated with lung
function in enriched pathways were overrepresented in regula-
tory regions as represented by DHSs. We found highly signiﬁcant
enrichment of DHSs among pathway-associated SNPs in relative
to all lung function GWAS SNPs [odds ratio 1.86, 95% conﬁdence
interval (1.73–2.00), P-value 1.75 × 10–68]. A similar analysis of
SNPs linked to enriched pathways associated with airﬂow ob-
struction revealed signiﬁcant overrepresentation of DHSs relative
to all airﬂow obstruction GWAS SNPs [odds ratio 1.65, 95% conﬁ-
dence interval (1.51–1.80), P-value 3.39 × 10–15].
Lung function-associated pathways aggregate within
distinct biologic modules
We applied unsupervised cluster analysis to the enriched path-
ways and their associated genes to determine segregation pat-
terns based on membership proﬁles and association P-values.
We deﬁned a module as a group of two or more gene sets (path-
ways) that clustered together based on sharing common gene
members. We found that a majority of enriched gene sets
mapped to biologically distinct functional modules (Fig. 2)—in-
cluding processes involved in Development, Cell Adhesion, Cell
Proliferation/Migration, Cell Signaling, Immunity, Ion Channel/
Transport and Arachidonic Acid/Prostaglandin. However, most
of the identiﬁed modules also shared member genes between
them, with particularly large overlaps among Development, Im-
munity, Adhesion, Cell Signaling and Proliferation/Migration
(Fig. 3).
Published literature strongly links enriched gene sets
derived from pulmonary function GWAS to lung biology
To assess whether the identiﬁed pulmonary function-associated
pathways and genes were implicated in lung biology, we system-
atically searched each pathway and gene via a PubMed mining
tool (PubMatrix) using the modiﬁer term ‘pulmonary function’.
As summarized in SupplementaryMaterial, Figure S3, everyover-
represented gene set had published reports for a role in pulmon-
ary biology, with immune system having the largest supporting
evidence (n = 57 847 citations) and several other pathways with
signiﬁcant publication records such as free radical pathway (n =
14 888), morphogenesis (n = 7324), epidermal growth factor sig-
naling (n = 1388) and Wnt signaling (n = 487). Many of the path-
way-associated genes were also highly cited, including tumor
necrosis factor (n = 8961), interleukin 8 (IL8, n = 4376), epidermal
growth factor receptor (n = 3549), transforming growth factor β1
(n = 1758) and cystic ﬁbrosis transmembrane conductance regula-
tor (n = 1630). Several genetic loci identiﬁed in our previous lung
function GWASs were members of enriched pathways and cited
in PubMed including advanced glycosylation end product-specif-
ic receptor (n = 196), hedgehog-interacting protein (n = 19) and
patched 1 (n = 15).
Pathway analysis of airﬂow obstruction GWAS reveals
many enriched gene sets including those involved in
tissue remodeling
The promising results from gene set analysis of pulmonary func-
tionmotivated us to expand this approach to airﬂow obstruction—
a clinically relevant spirometric phenotype characteristic of
obstructive lung disorders such as COPD. Applying the same
computational procedures to the airﬂow obstruction GWAS, we
identiﬁed 156 enriched gene sets at FDR < 0.001 (Supplementary
Material, Table S3). Unlike the two distinct lung function
GWASs, the airﬂow obstruction GWAS was a combined analysis
of CHARGE and SpiroMeta cohorts and therefore a two-step
validation strategy was impractical. Instead, we minimized
false-positive ﬁndings by applying a highly stringent FDR cutoff
to designate signiﬁcance.
We grouped enriched gene sets into biologic modules based
onmembership and functional overlap. The results are summar-
ized in Figure 4 and provide an overview of key pathways and pro-
cesses associated with airﬂow limitation. Since most of the
airﬂow obstruction cohorts had also participated in the lung
function GWASs and airﬂow obstruction is deﬁned based on spir-
ometry, it was not surprising that many of these enriched mod-
ules were also identiﬁed in the pulmonary function analysis,
including Development, Cell Signaling, Ion Channel, Cell Adhe-
sion and Proliferation. However, we also identiﬁed pathways
thatwere not enriched in the lung function analysis (Supplemen-
tary Material, Table S3). Prominent among these airﬂow obstruc-
tion-associated gene sets were processes involved in remodeling
of the extracellularmatrix (ECM), such as collagen, proteinaceous
ECM and integrin pathway. Since airway remodeling is a key
pathophysiologic characteristic of COPD, we further explored
the ECM module by mapping relationships among its members
using a comprehensive gene product interaction knowledgebase
(Ingenuity) (18). This analysis identiﬁed several distinct networks
within the ECM module, with the highest scoring network being
comprised of 21 interconnected focus genes as depicted in Fig-
ure 4 (see Supplementary Material, Table S6). Since nodal con-
nectivity in disease networks is a topologic property that can
indicate biologic importance (19,20), we selected the most
connected node in the ECM network, MMP10, as a candidate for
further functional validation.
MMP10 is a COPD candidate gene
We assessed the role of MMP10 in obstructive lung disease by
genetically targeting this gene in an established animal model
of emphysema. After chronic exposure to cigarette smoke,
wild-typemice developed extensive airwayand airspace destruc-
tion characteristic of emphysema, whereas Mmp10–/– animals
displayed only modest injury (Fig. 5A). Morphometric analysis
of acinar airspaces using the mean linear intercept method con-
ﬁrmed the protective phenotype observed in Mmp10-null mice
(Fig. 5B). To complement the morphometric assessment of lung
injury in our model, we measured the expression of interleu-
kin-1 beta (Il1b) and Mmp10. Il1b is a pro-inﬂammatory cytokine
upregulated in the lungs patient with COPD and a robust bio-
marker for frequent exacerbations (21). Overexpression of Il1b
causes abnormal airway remodeling and emphysema in mice
(22). We found that Il1b was signiﬁcantly increased in the lung
of wild-type animals after chronic cigarette smoke injury but
not in the emphysema-resistant Mmp10-null mice (Fig. 5C).
Mmp10 expression was similarly upregulated in wild-type mice
with emphysema, but remained undetectable in the knockouts
as expected (Fig. 5C). Collectively, these observations implicate
a pathophysiologic role for MMP10 in the development of cigar-
ette smoke-induced lung disease.
Discussion
Understanding the genetic basis of normal and impaired lung
function can provide new insights into the pathophysiology of
pulmonary disorders. Chronic respiratory conditions are a
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leading cause of death worldwide (3) and there is a recognized
need for new therapeutic targets (23). In this work, we initially le-
veraged two large, independent GWAS datasets totaling almost
50 000 subjects to systematically identify pathways associated
with lung function.We found a diverse set of interconnected bio-
logic modules linked to this trait. We extended this approach to
airﬂow obstruction—a clinically relevant phenotype deﬁned by
spirometry—and identiﬁed additional pathways associated
with obstructive lung disease. We functionally validated our
approach by demonstrating that MMP10, a member of an en-
riched airﬂow obstruction module (i.e. ECM), inﬂuences the se-
verity of cigarette smoke-induced emphysema using a genetic
mouse model.
To date, over 2000 GWASs encompassing hundreds of com-
plex traits and diseases have been published (24), with several
pertaining to pulmonary phenotypes including asthma (25–27),
idiopathic pulmonary ﬁbrosis (28), COPD (29,30), sarcoidosis (31)
and lung function (4,5,32). All of these studies have applied
Figure 2.Unsupervised hierarchical clustering of enriched pathways (gene sets) associated with pulmonary function. Rows representing enriched gene sets (n = 131) were
grouped based on overlapping gene membership (columns). Gene sets with many shared genes clustered together and deﬁne functional modules (e.g. cell signaling,
immunity and development). Columns represent gene membership proﬁles of enriched pathways and are colored according to association P-values of member genes.
Note that for any given gene set, the majority of pathway-associated genes are not members and are displayed as black bars. For each clustered group (module), only
representative pathways have been labeled. Complete list is available in Supplementary Material, Table S2.
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Bonferroni-type statistical cutoffs to minimize false-positive
SNP-to-phenotype associations. For example, our previous pul-
monary function GWASs identiﬁed numerous loci associated
with FEV1, FEV1/FVC, FVC and airﬂow obstruction (4,6,8,32). We
believe that those ﬁndings, while novel, did not comprehensively
capture the complex biological processes underlying these traits
because the standard GWAS approach is overly conservative and
discards biologically informative yet statisticallymodest associa-
tions. Enrolling larger cohorts can increase the number of loci (6),
but retains the individual SNP-focused structure of standard
GWAS. To overcome this limitation, pathway-focused ap-
proaches can complement standard GWAS and allow deeper
mining of genomic data (9). A key advantage of pathway enrich-
ment methodologies is their ability to place trait-associated can-
didates within the context of biologically meaningful pathways
andmodules. However pathway approaches have important lim-
itations, including the risk of false-positive ﬁndings and chal-
lenges in conﬁrming results, especially at a phenotypic level (33).
In this work, we aimed to circumvent some of these short-
comings by implementing a step-wise gene set enrichment ap-
proach, whereby ﬁndings from one pulmonary function GWAS
were conﬁrmed using an independent and similarly powered
GWAS (Fig. 1). We interrogated ∼2000 gene sets, but our two-
step validation substantially narrowed down these pathways to
a limited subset of 131 enriched pathways associated with pul-
monary function. Since pathway selection was ﬁltered by FDR
cutoffs (<0.05) at each stage, false-positive ﬁndings were strin-
gently controlled. Our approach of leveraging two independent
analyses addresses instabilities reported during attempts to rep-
licate gene set enrichment ﬁndings (34). The airﬂow obstruction
GWAS was a combined study using cohorts from both CHARGE
and SpiroMeta, precluding implementation of the step-wise
GSEA strategy. Therefore, we applied amuch stricter FDR thresh-
old (<0.001) to identify signiﬁcantly enriched gene sets and min-
imize false-positive associations. In both the lung function and
airﬂow obstruction GSEA, the number of pathways identiﬁed as
being enriched was <8% of the total gene sets surveyed, implying
that the vast majority of the curated pathways were not signiﬁ-
cantly associated with these traits.
Our comprehensive, pathway-focused analysis of pulmonary
function GWAS yielded several important results. First, we ob-
served that SNPs driving gene sets linked to lung function were
primarily those with moderate associations and not the GWAS-
signiﬁcant variants. These modestly signiﬁcant SNPs did not
reach genome-wide threshold, implying that standard GWAS
analysis fails to capitalize on a substantial segment of the avail-
able genomic information (9) (Supplementary Material, Fig. S2).
Secondly, enriched pathways clustered to a limited set of distinct
modules with speciﬁc functional roles, including development,
cell signaling and immunity (Fig. 2). The concept of a modular
network built from specialized yet interconnected pathways is
a fundamental property of complex biological systems (10,19).
Our ﬁndings were consistent with this paradigm and show that
each lung function-associated module—while comprised of
functionally similar gene sets—also sharedmany genemembers
with other modules (Fig. 3). We corroborated the biologic rele-
vance of the enriched gene sets by systematically literature-min-
ing each term and observed that all pathways and many of their
gene members had published links to ‘pulmonary function’, in
some cases numbering in the thousands (Supplementary Mater-
ial, Fig. S3). Furthermore, many SNPs linked to gene members of
enriched pathways were within regulatory DHSs, implying that
our approach captured functionally relevant genetic variants.
Pathway-based analysis of airﬂowobstruction GWAS revealed
multiple processes potentially involved in the pathogenesis of
COPD.Whilemany of the airﬂow obstructionmodules were simi-
lar to those associated with lung function, therewere substantial
differences between their respective gene sets (Supplementary
Material, Tables S2 and S3). Several of these pathways such as
transforming growth factor-β and phosphatidylinositol signaling
have been linked to the development of obstructive lung disease
(35–37). Another striking difference was selective enrichment of
gene sets involved in ECM. This ﬁnding is biologicallymeaningful
because COPD is characterized by structural destruction of
Figure 3. Wiring diagram of key biologic modules associated with lung function. These modules were derived from membership cluster analysis of enriched gene sets
(Fig. 2). Intermodular connectivity indicates overlapping genes between modules with the thickness of connections drawn proportional to the number of shared
genes—for example, development and immunity have 150 gene members in common.
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respiratory acini and ECM remodeling of small airways (38). The
network analysis of this module suggested that MMP10, a dense-
ly connected node, is a potential driver of ECM remodeling in air-
ﬂow obstruction, and hence we chose to study its role further
(Fig. 4).
MMPs are a family of ECM-associated proteins involved in di-
verse processes, including response to injury and inﬂammation,
tumor metastasis and remodeling (39–41). Our ﬁnding that
MMP10 may be associated with development of airﬂow obstruc-
tion is consistent with other reports implicating MMPs in COPD
(30). For example, a functional variant in MMP12 has been asso-
ciated with reduced risk of airﬂow obstruction in smokers (42),
and mice lacking this gene are protected from cigarette smoke-
induced emphysema (43). Furthermore, MMP10 was reported to
be differentially expressed in airway and surrounding lung par-
enchyma of COPD patients (44).
It is important to note that in our discovery lung function
GWAS the sentinel SNP in MMP10 (rs11225413) was far from
being genome-wide signiﬁcant (P = 0.03) andwould have been ex-
cluded if standard, Bonferroni-type adjustments had been
Figure 4. Graphical overview of enriched biological modules associated with airﬂow obstruction. Since the airﬂow obstruction GWAS was primarily based on the
pulmonary function GWASs, several of these modules overlap with those identiﬁed in the lung function analysis (Fig. 3). However, some modules such as apoptosis
and ECM were enriched only in airﬂow obstruction. Furthermore, even within common biologic modules, substantial differences in enriched gene sets were observed
between the two phenotypes with several representative pathways associated with airﬂow obstruction being highlighted. Deeper exploration of the ECM module
using gene product interaction network analysis identiﬁed MMP10 as the most interconnected node and a putative driver of ECM processes inﬂuencing airﬂow
obstruction. NOS, nitric oxide synthase; IGF1, insulin-like growth factor 1; TGF-β, transforming growth factor beta; EGF, epidermal growth factor; PDGF, platelet-
derived growth factor. Complete list is available in Supplementary Material, Table S3.
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applied. A joint SNP and SNP-by-smoking meta-analysis of this
SNP and other MMP10-associated variants did not reveal signiﬁ-
cant gene–environment interactions (7,45). Interestingly, inte-
grating network analysis with pathway-based data mining of
GWAS placedMMP10 within the context of other putative candi-
dates. For example, another member of the ECM network (Fig. 4),
Fibrillin 1, has been linked to development of early emphysema
in humans (46), andmicewith targeted knockout of this gene de-
velop spontaneous emphysema (47). Finally, our functional val-
idation of MMP10’s role using an animal model of emphysema
serves as a proof-of-concept that pathway-based approaches
have the potential to reveal disease-associated processes and
identify novel targets in complex disorders.
Our study has several limitations. We assumed that a given
SNP affects the function of its proximally located gene. This is
likely an over-simpliﬁcation of the biologic effects of genetic var-
iants since distal regulation can also occur (48). However, there is
no accepted method to comprehensively assess the global inﬂu-
ence of SNPs on gene function in humans. Analysis of expression
quantitative trait loci (eQTL) can be useful for functional
validation (49,50), but is based solely on the transcriptional
effects of genetic variants, ignoring any post-transcriptional
consequences. Furthermore, eQTLs exhibit signiﬁcant tissue
and even cell-type speciﬁcity (51,52) and require large sample
sizes to achieve adequate power. Not surprisingly, many signiﬁ-
cant trait-associated SNPs do not have strong eQTLs. Thus, for
our GSEA, we opted to not ﬁlter candidate SNPs based on limited
eQTL information. However, we observed highly signiﬁcant en-
richment of DHSs among pathway-associated SNPs, implying
overrepresentation of functional variants in our approach. An-
other inherent shortcoming of pathway-based methods is their
reliance on known biologic processes and gene functions, im-
pairing their ability to discover novel mechanisms or relation-
ships. Nevertheless, previously unrecognized processes can be
implicated in a given trait since enriched biologic modules are
placed within a phenotype-speciﬁc context without bias. Our lit-
erature-mining effort was, by deﬁnition, based on available
knowledge. In future studies, it will be of particular interest to in-
vestigate members of enriched gene sets that did not have pub-
lished evidence of involvement in lung biology. Finally, since
irreversible airﬂow obstruction is a required criterion for diagno-
sis of COPD andwe did not assess bronchodilator response in our
spirometricmeasurements,we have refrained from labeling indi-
viduals with airﬂow obstruction as having COPD.
Figure 5. Mmp10–/– mice are resistant to cigarette smoke-induced emphysema. (A) Representative H&E lung sections of Mmp10–/– and wild-type animals exposed to 6
months of chronic cigarette smoke demonstrated extensive injury in wild types with signiﬁcant loss of acinar and small airway structures (top row). In contrast,
Mmp10-null mice were substantially less susceptible to smoke-induced emphysema (bottom row). Slides are ordered according to severity of lung injury in each
genotype. (B) Morphometric analysis of airspaces using the mean linear intercept method conﬁrmed the protective phenotype observed in Mmp10–/– mice (n = 10 for
smoke exposed Mmp10–/– mice, n = 9 for all other groups). (C) Wild-type mice exposed to chronic cigarette smoke have signiﬁcantly increased expression of the pro-
inﬂammatory cytokine Il1b as well as Mmp10 in their lungs, whereas emphysema-resistant Mmp10–/– animals do not (n = 8 per group). All P-values based on two-tailed
Student’s t-test; NS, not signiﬁcant.
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In conclusion, by integrating pathway analysis with multiple
GWASs, we have comprehensively mapped processes inﬂuen-
cing lung function and airﬂow obstruction. While many of the
identiﬁed gene sets have been previously linked to pulmonary
biology in animal models or limited human tissue samples, our
approach derived its genomic information from large human co-
horts, making its ﬁndings broadly relevant to the general popula-
tion. The proposed framework, therefore, may have particular
applicability in dissecting disease mechanisms in complex lung
diseases with available GWAS.
Materials and Methods
GWAS of lung function traits
CHARGE and SpiroMeta cohorts were independently meta-ana-
lyzed for GWAS of pulmonary function. All subjects were of Euro-
pean ancestry and underwent spirometry to assess lung function
based on forced expiratory volume in 1 s (FEV1) and its ratio to
forced vital capacity (FEV1/FVC). In the ﬁrst phase, we analyzed
data from seven cohorts totaling 25 366 subjects within the
CHARGE consortium. For the validation step, we meta-analyzed
data from 17 cohorts with 24 583 individuals within the SpiroMeta
consortium.
The analysis of airﬂow obstruction was based on a combined
GWASmeta-analysis of 14 CHARGE and SpiroMeta cohorts total-
ing 31 567 participants of European ancestry (3056 affected,
28 511 unaffected) (8). These participants constituted a subset
of the total subjects analyzed in the CHARGE and SpiroMeta
lung function GWASs described above.We used standardized de-
ﬁnitions of airﬂowobstruction based on the lower limit of normal
for FEV1 and FEV1/FVC fromNHANES III prediction equations (53)
across all cohorts. The presence of airﬂow obstruction was de-
ﬁned as an FEV1 and FEV1/FVC both less than the lower limit of
normal (54), which is calculated from gender-speciﬁc equations
for age, age2 and height2. Unaffected participants were deﬁned
by FEV1, FVC and FEV1/FVC all above the lower limit of normal. In-
dividuals below the lower limit of normal for either FEV1 or FEV1/
FVC but not both were excluded from these analyses. Therefore,
unlike lung function, the presence of airﬂow obstruction was de-
ﬁned dichotomously.
GWAS procedures
Genotyping, imputation, genotype-phenotype association and
meta-analysis procedures for lung function and airﬂow obstruc-
tion in CHARGE and SpiroMeta consortia have been previously
described (4,5,8). Non-genotyped SNPs were imputed using
MACH, IMPUTE or BIMBAM. Linear regression for age, age2, sex,
height and ancestry principal components as covariates was per-
formed on FEV1 (mm) and FEV1/FVC (%). Residuals were ranked
and then transformed to z-scores andused for association testing
under an additive genetic model stratiﬁed by ever-smoking and
never-smoking status. Effect estimates were meta-analyzed
using inverse-variance weighting across the cohorts in each con-
sortiumusing R (version 2.9.2) orMETAL (55) and genomic control
correction (56) was applied. In the airﬂow obstruction GWAS, for
each cohort logistic regression models were adjusted for current
and former smoking dummy variables, pack-years of smoking,
age, sex, standing height, center/cohort as needed, and principal
components for genetic ancestry as needed.While heterogeneity
was observed across cohorts, implementation of a ﬁxed effects
model was effective in extracting homogeneous ﬁndings. Gen-
ome-wide meta-analyses were performed using METAL with in-
verse-variance weighting to combine effect size estimates after
applying a genomic control correction. QQ plots of expected
and observed association P-values on a –log10 scale for CHARGE
and SpiroMeta FEV1 and FEV1/FVC GWASs was created using
local scripts in R (http://www.R-project.org/).
Gene set enrichment analysis of GWAS
We applied a methodology called improved GSEA for GWAS (i-
GSEA4GWAS) to place variants associated with pulmonary func-
tion or airﬂow obstruction within curated pathways (16). Geno-
typed and imputed SNPs from lung function GWAS (n≈ 2.5 × 106)
were mapped to genes within a 100 kb distance (upstream or
downstream). No ﬁltering of SNPs based on LD structure or associ-
ation P-valuewas performed prior to the enrichment analysis. For
a given SNP, if multiple genes were located within this range, the
closest gene was selected and assigned the association P-value.
The SNP with the strongest association P-value was used to re-
present a gene. Since multiple SNPs can map to the same gene,
an SNP label permutation was used to reduce potential biases
caused by larger loci having disproportionately higher number of
SNPs. Log-transformed association P-values (–log10P) were used to
rank order the resulting gene list (∼18 000 genes) and calculate
gene set enrichment scores. The i-GSEA4GWAS procedure calcu-
lates a signiﬁcance proportional enrichment score that is based
on the proportion of signiﬁcant genes mapped to a given gene set
relative to the proportion of signiﬁcant genes across total genes in
the GWAS. Approximately 2000 gene sets were obtained from
the Molecular Signatures Database (http://www.broadinstitute.
org/gsea/msigdb) (15,57). To maximize biologic relevance, gene
sets were deﬁned and limited to well-curated pathways derived
from multiple resources such as KEGG, BioCarta, REACTOME
and functional annotations extracted from the Gene Ontology
database. Therefore, the terms ‘gene set’ and ‘pathway’ are used
interchangeably.
Step-wise validation of functional enrichment analysis
for pulmonary function
A two-step approach was taken to independently validate en-
riched pathways associated with lung function. The i-GSEA4G-
WAS algorithm was initially applied to the CHARGE pulmonary
function GWAS and enriched gene sets were identiﬁed if they
met an FDR < 0.05 for either FEV1 or FEV1/FVC. Next, the same
procedure was implemented in the SpiroMeta consortium
GWAS for FEV1 and FEV1/FVC. We restricted further analysis to
those enriched pathways in CHARGE (FDR < 0.05) that were also
signiﬁcantly enriched in SpiroMeta (FDR < 0.05). Since these two
large cohorts are independent, this requirement ensured strict
control of false-positive ﬁndings. For the airﬂow obstruction path-
way analysis, we used the available combined CHARGE and Spiro-
Meta meta-analyzed GWAS (8) and chose a much more stringent
FDR < 0.001 to designate signiﬁcant gene set enrichment.
Sensitivity analyses of gene set enrichment
Since several distinct analytical methods exist for pathway en-
richment analysis and applying different algorithms to the
same GWAS data may yield different results, we compared the
performance of i-GSEA4GWAS against another pathway-based
approach known as GSA-SNP (17). There are fundamental differ-
ences between the two methods, including the statistical frame-
work used to assess enrichment aswell as the size and content of
the gene sets. We used the default z-statistic for enrichment and
second-best SNP to randomly associated signals in GSA-SNP. We
queried Gene Ontology and KEGG databases for gene sets. We
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performed an identical, two-stage analysis on CHARGE followed
by SpiroMeta lung function GWASs using GSA-SNP.We identiﬁed
over 300 enriched processes (at FDR < 0.05 in CHARGE that were
also signiﬁcant at FDR < 0.05 in SpiroMeta). While this was a lar-
ger number than identiﬁed using iGSEA4GWAS (n = 131), it likely
reﬂected the fact that GSA-SNP sampled amuch larger number of
gene sets, whereas the proportion of identiﬁed signiﬁcant gene
sets is similar between the two approaches. Approximately
one-quarter of the pathways identiﬁed by iGSEA4GWAS (32 of
131) were identical to those identiﬁed as signiﬁcant by GSA-SNP
even though iGSEA4GWAS included several data resources not
sampled in GSA-SNP. Overall, there was substantial overlap be-
tween the two methods when the enriched gene sets were
grouped based on broader functional modules as deﬁned in Fig-
ures 2 and 3. A detailed comparison between the enriched gene
sets identiﬁed by each approach is provided in Supplementary
Material, Table S4.
We did not ﬁlter SNPs based on LD structure prior to initiating
enrichment analysis in order to retain genome-wide coverage and
prevent loss of information. The statistical structure of iGSEA4G-
WAS is based on associating a single sentinel SNP with its prox-
imal gene locus (100 Kb window) without being inﬂuenced by its
association with other potential SNPs in LD. Nevertheless, it was
possible that the selected sentinel SNPs themselves may be in
LD. Therefore, we systematically assessed pairwise LD between
all 3307 pathway-associated SNPs using SNAP (https://www.
broadinstitute.org/mpg/snap/ldsearchpw.php) at r2 thresholds of
0.2, 0.5 and 0.8.We found limited evidence for LD between the sen-
tinel SNPs (Supplementary Material, Table S5).
Next, we repeated the entire iGSEA4GWAS analysis for lung
function using a wider window (1 Mb versus 100 Kb) to associate
proximal SNPs with loci. We observed over 70% identical match-
ing between enriched pathways using the wider window, sug-
gesting that the SNP to gene locus selection approach is robust
to a range of selected windows. This observation is also consist-
ent with our above ﬁnding that most pathway-associated SNPs
are not in LD.
Cluster analysis
Two-way unsupervised hierarchical clusteringwas performed on
enriched pathways in lung function based on the membership
proﬁle of gene sets and their associated genes’ log-transformed
P-values (–log10P) using Pearson’s correlation metric (58). In this
approach, gene sets were initially labeled by the presence or ab-
sence of any lung function-associated genes and then clustered
together based on shared genemembers to form larger, function-
ally coherent pathway groupings deﬁned as ‘modules’.
Literature mining
We used PubMatrix (59), an online multiplex comparison tool for
querying ‘search’ and ‘modiﬁer’ terms within PubMed, to index
published literature on the role of enriched gene sets and their
associated gene members in inﬂuencing lung function. The
search terms were either pathway-associated gene symbols
(n = 3878) or pathway names (n = 131), and the modiﬁer term
was ‘pulmonary function’.
DNAse I hypersensitive site enrichment analysis
The frequency that SNPs selected for pathway analysis fell
within DHS sites was compared with the frequency that all
SNPs analyzed in the GWAS were located in DHSs. All SNPs
were converted to their UCSC hg19 assembly positions using
liftOver (http://genome.ucsc.edu). Sentinel SNPs associated with
enriched pathways (one SNP per gene) and entire GWAS sets
were intersected with the complete set of DHS hotspot regions
(FDR < 0.05) identiﬁed in any of the 349 tissue or cell line samples
available from Maurano et al. (48). The intersection was calcu-
lated using the BEDOPS software (60). The enrichment P-values
were calculated using Fisher’s exact test based on the total
probability of two-tailed test. The frequency of lung function
pathway-associated SNPs was compared with the union set of
SNPs analyzed in the CHARGE and SpiroMeta lung function
GWASs. The airﬂow obstruction pathway-associated SNPs were
compared relative to all SNPs in the airﬂow obstruction GWAS.
Network analysis
We imported all 89 ECM-associated genes into Ingenuity software
and used its network-generating algorithm to develop interaction
networks built around these ‘focus genes’ using Ingenuity’s
knowledge base. We used only direct gene product interactions
to link nodes, and excluded any non-focus genes added by the al-
gorithm to grow the network. Networks were ranked based on
Fisher’s exact test of enrichment relative to networks generated
from randomly selected genes from Ingenuity’s knowledge base
(Supplementary Material, Table S6). Subsequent analysis was
based on the highest ranked ECM network that included the lar-
gest number of focused genes (n = 23 ECM-associated genes of
which 21 had direct interactions with each other).
Animal experiments
The Institutional Animal Care and Use Committees at the Univer-
sity of Washington and Washington University in St. Louis ap-
proved all animal experiments. We generated Mmp10-null mice
on a C57BL/6 background (61). These mice are healthy with no
overt defects in fertility, litter size, gross appearance, organ struc-
ture or tissuehistology. AdultmaleMmp10–/– (n = 10) andwild-type
(n = 9) mice were exposed to the smoke of four ﬁltered cigarettes
(2R4F, Kentucky Tobacco Research and Development Center, Uni-
versity of Kentucky) per day, 6 days perweek for 6months. An un-
exposed group of age and sex-matched Mmp10–/– (n = 9) and wild
types (n = 9) were used as controls. The exposure experiments
wereperformed in theCigaretteSmokeExposureCore atWashing-
ton University, St. Louis. Upon completion of exposure experi-
ments, all animals were killed by an intraperitoneal injection of
a Tribromoethanol (Avertin) overdose and exsanguinated by cut-
ting the caudal vena cava. Lungs were cannulated and inﬂated
with neutral buffered formalin at a constant ﬂuid pressure of
25 cm for 5 min. Lungswere removed, immersed in formalin over-
night, washed with graded increasing concentrations of ethyl al-
cohol, and subsequently embedded in parafﬁn and sectioned.
Structural changes caused by chronic cigarette smoke exposure
between the genotypes were assessed in the Histology and Im-
aging Core at the University of Washington using morphometry
based on a modiﬁcation of the direct estimation of mean chord
length from a set of random intercepts applied to H&E stained tis-
sue sections (62).Whole slide imageswere acquired using a Nano-
zoomer (Hamamatsu model C9600) to scan entire right lung
sections and were uploaded into Visiopharm image analysis soft-
ware. The software provided 50 random images covering all lobes
of the right lung, created two randomly oriented lines traversing
the image, andprovided the sampling tools necessary tomanually
measure distance along the test lines between airspace walls.
Mean chord lengthwas calculated for eachmouse fromall images
counted.
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Quantitative real-time PCR (qPCR) was performed on total
RNA isolated using Trizol (Invitrogen, Carlsbad, CA, USA) from
whole lung ofwild-type andMmp10–/–mice exposed to the chron-
ic cigarette smoke protocol described above (n = 8 per group). RNA
was quantiﬁed using a Nanodrop spectrophotometer (Thermo
Scientiﬁc, Waltham, MA, USA) and 3–5 µg of total RNA was re-
verse transcribed using a High-Capacity cDNA Archive kit (Ap-
plied Biosystems, Foster City, CA, USA). qPCR was performed in
duplicates on an ABI HT7900 Fast Real-Time PCR System using
TaqMan Gene Expression assays forMmp10 and Il1b (Applied Bio-
systems) in duplicates. The threshold cycle (Ct) was determined
by instrument software and data expressed as relative quantiﬁ-
cation calculated using 2–ΔΔCt for each gene and using hypoxan-
thine phosphoribosyltransferase (HPRT) as the reference gene.
HPRT Ct levels ranged between 23 and 25 in all assays.
Supplementary Material
Supplementary Material is available at HMG online.
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